EP. 1: Antibody Drug Conjugates and Interstitial Lung Disease Risk
EP. 2: Risks for Developing ILD and Personal Experience
EP. 3: Changes in Cancer Treatment and Management of ILD
EP. 4: Use of Antibody Drug Conjugates and Potential for ILD
EP. 5: Rate and Class Effect of ILD with Antibody Drug Conjugates
EP. 6: CDK 4/6 Inhibitors and Identifying ILD in Patients
EP. 7: Managing Patient Symptoms and Clinician Education
EP. 8: Drug-Induced ILD and Rate of Occurrence in GI Cancer Trials
EP. 9: Patient Factors for Developing ILD and Personal Experience
EP. 10: Patient Management upon Developing ILD and Education
EP. 11: Potential Risk of Drug-Induced Interstitial Lung Disease
EP. 12: Personal Experience with Drug-Induced ILD
EP. 13: Rate of ILD and Monitoring Parameters
EP. 14: Identifying Drug-Induced ILD
EP. 15: Patient Management and Educational Tools for ILD
EP. 16: Role of Antibody Drug Conjugates and Personal Experience
EP. 17: Risks for Developing ILD in Gastrointestinal Cancer Studies
EP. 18: Risk of ILD as a Class Effect and Identifying ILD
EP. 19: Changes in Treatment Goals due to Drug Induced ILD
EP. 20: Management of Patients Who Develop ILD
EP. 21: Educational Tools for Possible Drug-Induced ILD